Akums Drugs & Pharmaceuticals Share Price
₹572.80 +12.2 (2.18%)
21 Dec, 2024 18:49
Start SIP in AKUMS
Start SIPPerformance
- Low
- ₹552
- High
- ₹590
- 52 Week Low
- ₹530
- 52 Week High
- ₹1,176
- Open Price₹562
- Previous Close₹561
- Volume553,477
Investment Returns
- Over 1 Month -1.35%
- Over 3 Month -32.75%
- Over 6 Month -15.64%
- Over 1 Year -15.64%
Smart Investing Starts Here Start SIP with Akums Drugs & Pharmaceuticals for Steady Growth!
Akums Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 32.5
- PEG Ratio
- -
- Market Cap Cr
- 9,016
- P/B Ratio
- 12.5
- Average True Range
- 26.7
- EPS
- 17.41
- Dividend Yield
- 0
- MACD Signal
- -41.6
- RSI
- 33.74
- MFI
- 39.86
Akums Drugs & Pharmaceuticals Financials
Akums Drugs & Pharmaceuticals Technicals
EMA & SMA
Current Price
₹572.80
+
12.2
(2.18%)
- Bullish Moving Average 0
- Bearish Moving Average 11
- 20 Day
- ₹611.27
- 50 Day
- ₹690.91
- 100 Day
- -
- 200 Day
- -
Resistance and Support
571.68
- R3 628.57
- R2 609.23
- R1 591.02
- S1 553.47
- S2 534.13
- S3 515.92
Akums Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2024-11-09 | Quarterly Results | |
2024-08-24 | Quarterly Results |
Akums Drugs & Pharmaceuticals F&O
About Akums Drugs & Pharmaceuticals
- NSE Symbol
- AKUMS
- BSE Symbol
- 544222
- Managing Director
- Mr. Sanjeev Jain
- ISIN
- INE09XN01023
Similar Stocks to Akums Drugs & Pharmaceuticals
Akums Drugs & Pharmaceuticals FAQs
Akums Drugs & Pharmaceuticals share price is ₹572 As on 21 December, 2024 | 18:35
The Market Cap of Akums Drugs & Pharmaceuticals is ₹9015.5 Cr As on 21 December, 2024 | 18:35
The P/E ratio of Akums Drugs & Pharmaceuticals is 32.5 As on 21 December, 2024 | 18:35
The PB ratio of Akums Drugs & Pharmaceuticals is 12.5 As on 21 December, 2024 | 18:35
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.